Kansas City, Missouri 2021-06-10 14:58:49 –
For over 50 years, cannabis research has been limited to marijuana from one federal-approved facility in Mississippi.
The DEA now states that more companies can provide marijuana for research, eliminating obstacles to learning about the medical properties of narcotics.
“For example, I think it was difficult for (National Institute of Substance Abuse) (at least its program) to keep up with that trend, as the potency of street products increased to 12% 15%,” said Dr. Igor Grant. I will. Director of the Medical Cannabis Research Center at the University of California, San Diego.
Grant also states that it is difficult for a single company to keep up with the demand from researchers across the country.
He also said the new DEA policy would increase the diversity of research products. Previously, researchers could only study smokeable cannabis, excluding products such as THC cream that could be used to treat pain and pain.
Dr. Sue Sisley, president and senior researcher at the Scottsdale Institute, said past DEA regulations have restricted her research on marijuana as a treatment for PTSD in veterans.
“Now we finally have the right investigational drug to help these veterinarians discover new treatments,” Sisley said.
Having a real form of cannabis for research will also provide the patient with the coveted answer.
“All of this strain science, such as which strain is best for which disease, could not be done because the strains available at the University of Mississippi were so limited,” Sisley said. ..
Having more information about medical marijuana allows researchers to warn people if cannabis should be used with certain prescription medications, especially for the elderly.
“Blood pressure, diabetes, or whatever it is, are all areas that need to be considered, regardless of whether they are smoked or taken orally, and how they are administered,” Grant said.
Both researchers agree that relaxed regulation is a big step forward for medical cannabis, but it still has a long way to go.
Sisley has launched a new push in federal court to reclassify marijuana drug schedules.Currently marijuana is by DEA Schedule I medicine — Same classification as heroin and LSD.
Loosened regulations on medical marijuana research could provide advances in treatment Source link Loosened regulations on medical marijuana research could provide advances in treatment